Suppr超能文献

他汀类药物作为痛风患者一级预防的效果:基于人群的队列研究。

Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study.

机构信息

1 Institut Universitari d'Investigació en Atenció Primària Jordi Gol ( IDIAJGol), Catalonia, Spain.

2 ISV Research Group, Research Unit in Primary Care, Catalonia, Spain.

出版信息

J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):542-550. doi: 10.1177/1074248419857071. Epub 2019 Jun 27.

Abstract

BACKGROUND

Cardiovascular guidelines do not give firm recommendations on statin therapy in patients with gout because evidence is lacking.

AIM

To analyze the effectiveness of statin therapy in primary prevention of coronary heart disease (CHD), ischemic stroke (IS), and all-cause mortality in a population with gout.

METHODS

A retrospective cohort study (July 2006 to December 2017) based on Information System for the Development of Research in Primary Care (SIDIAP), a research-quality database of electronic medical records, included primary care patients (aged 35-85 years) without previous cardiovascular disease (CVD). Participants were categorized as nonusers or new users of statins (defined as receiving statins for the first time during the study period). Index date was first statin invoicing for new users and randomly assigned to nonusers. The groups were compared for the incidence of CHD, IS, and all-cause mortality, using Cox proportional hazards modeling adjusted for propensity score.

RESULTS

Between July 2006 and December 2008, 8018 individuals were included; 736 (9.1%) were new users of statins. Median follow-up was 9.8 years. Crude incidence of CHD was 8.16 (95% confidence interval [CI]: 6.25-10.65) and 6.56 (95% CI: 5.85-7.36) events per 1000 person-years in new users and nonusers, respectively. Hazard ratios were 0.84 (95% CI: 0.60-1.19) for CHD, 0.68 (0.44-1.05) for IS, and 0.87 (0.67-1.12) for all-cause mortality. Hazard for diabetes was 1.27 (0.99-1.63).

CONCLUSIONS

Statin therapy was not associated with a clinically significant decrease in CHD. Despite higher risk of CVD in gout populations compared to general population, patients with gout from a primary prevention population with a low-to-intermediate incidence of CHD should be evaluated according to their cardiovascular risk assessment, lifestyle recommendations, and preferences, in line with recent European League Against Rheumatism recommendations.

摘要

背景

心血管指南并未针对痛风患者的他汀类药物治疗给出明确建议,因为缺乏相关证据。

目的

分析痛风患者中他汀类药物治疗在冠心病(CHD)、缺血性卒中(IS)一级预防中的有效性,以及全因死亡率。

方法

基于初级保健研究开发信息系统(SIDIAP)的回顾性队列研究(2006 年 7 月至 2017 年 12 月),这是一个电子病历研究质量数据库,纳入了无既往心血管疾病(CVD)的初级保健患者(年龄 35-85 岁)。参与者分为他汀类药物未使用者或新使用者(定义为在研究期间首次接受他汀类药物治疗)。新使用者的索引日期为首次开具他汀类药物,随机分配给未使用者。使用 Cox 比例风险模型调整倾向评分比较 CHD、IS 和全因死亡率的发生率。

结果

2006 年 7 月至 2008 年 12 月期间,共纳入 8018 名患者,其中 736 名(9.1%)为新使用者。中位随访时间为 9.8 年。CHD 的粗发病率分别为新使用者和未使用者每 1000 人年 8.16(95%置信区间 [CI]:6.25-10.65)和 6.56(95% CI:5.85-7.36)事件。CHD 的风险比为 0.84(95% CI:0.60-1.19),IS 为 0.68(0.44-1.05),全因死亡率为 0.87(0.67-1.12)。糖尿病的风险为 1.27(0.99-1.63)。

结论

他汀类药物治疗与 CHD 的临床显著降低无关。尽管与普通人群相比,痛风患者的 CVD 风险较高,但来自 CHD 发病率低至中等的初级预防人群的痛风患者,应根据其心血管风险评估、生活方式建议和偏好进行评估,这与最近的欧洲抗风湿病联盟建议一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验